Current Support
NIH/NIAID/NICHD & Johns Hopkins University (UM1 AI068632), “IMPAACT leadership group – 2005” (2020-2027). Garcia-Prats, Protocol Vice Chair
NIH/NIAID/NICHD & Johns Hopkins University (UM1 AI068632), “IMPAACT leadership group – 2034” (2021-2025). Garcia-Prats, Protocol Co-Vice Chair
Pediatric Infectious Diseases Society, “Enhanced detection of treatable infections in children with severe acute malnutrition in Malawi” (2022-2024). Garcia-Prats, Mentor
Unitaid & Stellenbosch University, “BENEFIT kids: Better evidence and formulations for improved MDR-TB treatment in children” (2019-2024). Garcia-Prats, PI
Thrasher Research Fund, “Novel strategies to improve tuberculosis case finding in children with severe acute malnutrition” (2021-2023). Garcia-Prats, Mentor
Completed Support
NIH/Fogarty International Center & University of North Carolina at Chapel Hill (D43 TW009340), “UJMT Fogarty global health fellowship program” (2022-2023). Garcia-Prats, Mentor
WHO/Global Accelerator for Paediatric Formulations (GAP-f), “CHEETA (chasing expedited and equitable treatment access for children with TB) task force” (2022). Garcia-Prats, PI
Novartis Pharmaceuticals, “A phase I/II study of the pharmacokinetics, safety and tolerability of clofazimine in HIV-infected and uninfected children treated for rifampicin-resistant tuberculosis” (2019-2021). Garcia-Prats, Protocol Co-Chair
NIH/NIAID & IMPAACT (TO13, Study 006), “Assay development and testing to support bedaquiline and delamanid use for MDR-TB treatment in special populations including children and lactating women” (2019-2021). Garcia-Prats, PI
NIH/NIAID/NICHD & Johns Hopkins University (UM1 AI068632), “IMPAACT 2020: Shortened oral treatment for multidrug-resistant tuberculosis in infants, children and adolescents (SMaRT Kids): A phase III, randomized, multi-center trial” (2017-2021). Garcia-Prats, Protocol Chair
NIH/NICHD/NIAID (R01 HD083047), “Optimizing and operationalizing pediatric drug-resistant tuberculosis treatment” (2015-2020). Garcia-Prats, MPI
NIH/NIAID (UM1 AI069521), “Stellenbosch University clinical trial unit (SUN-CTU); Clinical research site 31790, Desmond Tutu TB Centre, IMPAACT network” (2013-2020). Garcia-Prats, Co-Investigator
Unitaid, “Project preparation facility for BENEFIT kids: Better evidence and formulations for improved MDR-TB treatment for children” (2018-2019). Garcia-Prats, PI
TB Alliance, “Optimizing rifampicin exposure in children (Opti-Rif): A phase I/II open label multi-cohort dose escalation study to evaluate the pharmacokinetics and safety of increased doses of rifampicin in HIV-negative children with tuberculosis” (2017-2019). Garcia-Prats, Co-Investigator
British MRC/South African MRC (MR/M007340/1), “TB-CHAMP (Tuberculosis child multidrug-resistant preventive therapy trial): A phase III cluster randomized placebo-controlled trial to assess the efficacy of preventive therapy in child contacts of multidrug-resistant tuberculosis” (2015-2019). Garcia-Prats, Co-Investigator
Otsuka Pharmaceuticals (Otsuka 242-12-232 and 242-12-233), “Phase 1, open-label, multidose, and age de-escalation trial to assess the pharmacokinetics, safety and tolerability of delamanid (OPC 67683) in paediatric multidrug-resistant tuberculosis patients on therapy with an optimized background regimen of anti-tuberculosis drugs, and phase 2, open-label, multiple-dose trial to assess the safety, tolerability, pharmacokinetics, and efficacy of delamanid (OPC 67683) in pediatric multidrug-resistant tuberculosis patients on therapy with an optimized background” (2014-2019). Garcia-Prats, Site PI
NIH/WHO/Unitaid, “WHO research toolkit to support drug and formulation development for infants, children and adolescents living with HIV” (2017-2018). Garcia-Prats, Co-infections Module Co-leader
NIH/NIAID (UM1 AI068632), “IMPAACT leadership group – Co-chair TASK002 (BDQ Crush Study)” (2015-2017). Garcia-Prats, Protocol Co-Chair
Thrasher Research Fund, “Pediatric tuberculosis – Enabling early detection of children at risk for poor treatment outcomes” (2013-2017). Garcia-Prats, Co-Investigator
NIH (R01 HD069169), “The pharmacokinetics and safety of second-line TB drugs in HIV-infected and –uninfected children with MDR-TB” (2012-2016). Garcia-Prats, Co-Investigator